ClinicalTrials.gg
RecruitingNCT06641791Updated Oct 14, 2026

Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer

A Phase 3 interventional study of Standard Radiotherapy (SRT) and Stereotactic Body Radiotherapy (SBRT) in Advanced Head and Neck Cancer, sponsored by Canadian Cancer Trials Group. Recruiting at 10 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Canadian Cancer Trials Group · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Oct 14, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 202 studies in Head and Neck Neoplasms with a site in Canada — 32 open to participants now, 56 under way, 11 of them phase 3. Head and Neck Neoplasms · Canada.

Planned enrollment
46th of 170
196 · median 70
Started
2025
with 9 others
Phase 3
39 of 202
5 open now
Primary completion
2031-01
later than 53 of 55 live
Registered
193rd of 202
by date

Among the 202 studies in Head and Neck Neoplasms with a site in Canada, this one is the 46th largest by planned enrollment of the 170 interventional ones that give a count, is one of 10 that started in 2025, is one of 39 in phase 3, reaches primary completion later than 53 of the 55 other live ones, and was the 193rd registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

32 of the 202 studies in Head and Neck Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies in Head and Neck Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

This study is being done to answer the following question: Does stereotactic body radiation therapy (SBRT) provide better cancer control compared to standard radiation therapy (RT) for those with advanced head and neck cancer?

Read the detailed description

Stereotactic body radiation therapy, or SBRT, is a cancer treatment that more precisely delivers radiation to the tumour area with less radiation going to unaffected areas around the tumour. It uses fewer treatments of higher doses compared to standard radiation therapy.

This study is being done to find out if this approach is better than the usual approach for advanced head and neck cancer. The usual approach is defined as care most people get for advanced head and neck cancer.

03

Conditions studied

  • Advanced Head and Neck Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed mucosal squamous cell carcinoma (SCC) of the head and neck arising from at least one of the following sites: oro/hypopharynx, oral cavity, supraglottic larynx, maxillary sinus, nasal cavity, or unknown primary
  • Stages TX or T0-T4/N0-N3
  • Must be considered unfit for curative intent RT as determined by the treating oncologist(s)
  • Geriatric 8 score \<14
  • Patient must be ≥18 years of age
  • Staging CT or MRI of the head and neck within 8 weeks prior to randomization
  • Chest CT or x-ray. PET CT is permitted if CT is of diagnostic quality.
  • (ECOG) Performance Status 0-3
  • Participants of must have agreed to use a highly effective method during protocol therapy.
  • Patients with a prior whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the treatment are eligible for this trial.

Exclusion criteria

Exclusion Criteria:

  • Patients with nasopharyngeal carcinoma.
  • Prior systemic therapy (including immunotherapy).
  • Prior radiotherapy to the head and neck excluding superficial radiotherapy for head and neck skin cancer that does not overlap with current protocol treatment.
  • Prior head and neck cancer excluding skin cancer.
  • Patients with tumour locations/at risk of SBRT toxicity, including glottic/subglottic larynx, T4 hypopharynx, post-cricoid, cervical esophagus, circumferential pharyngeal involvement, extension/proximity to brain/optic structures, any single tumour mass >8 cm (in one dimension).
  • > 2 nodal levels (Level 1a/b not counted); retropharyngeal lymph nodes (where the closest edge is \< 2cm from the closest edge of CTV (primary or nodal) will not be considered as a different level). Note: a single lymph node mass that spans 2 levels will be considered as 1 level.
  • Gross tumour poorly visualized on CT/MRI.
  • Definitive radiological or clinically evident distant .
  • Scleroderma/CREST syndrome.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
196 participants (estimated)

Study arms

  • Active comparator
    Standard Radiotherapy (SRT)

    Radiation: Standard Radiotherapy (SRT)

  • Experimental
    Stereotactic Body Radioterapy (SBRT)

    Radiation: Stereotactic Body Radiotherapy (SBRT)

Interventions

  • RadiationStandard Radiotherapy (SRT)

    2400 cGy in 3 fractions - day 0/7/21, OR, 2500 cGy in 5 fractions over 1 week

  • RadiationStereotactic Body Radiotherapy (SBRT)

    4500 cGy in 5 fractions (twice a week to primary and nodal GTV, OR, 4000 cGy in 5 fractions twice a week if organs at risk.

06

What researchers measure

Primary outcomes

  1. Overall Survival estimated according to Kaplan-Meier's methodology

    Time frame: 6 years

Secondary outcomes

  1. Progression-free Survival

    Time frame: 6 years

  2. Local Regional Failure Free Survival

    defined as the time from the date of randomization to the date of any of the following, whichever comes first: * The first record of appearance (radiological or clinical) of local or regional disease progression/recurrence. * Surgery of primary tumour at any time performed for clinical or radiological (RECIST 1.1) disease persistence/progression/recurrence with tumour present/unknown on final pathology. * Neck dissection \> 20 weeks from the end of radiation therapy performed for clinical or radiological (RECIST 1.1) disease persistence/progression/recurrence with tumour present/unknown on final pathology.

    Time frame: 6 years

  3. Response Rate evaluated by RECIST

    Time frame: 6 years

  4. Number and Severity of Adverse Events

    Time frame: 6 years

  5. Patient Reported Outcomes utilizing PRO-CTCAE

    We will qualitatively compare PRO-CTCAE item scores between arms at 8 weeks from the start of RT, and examine PRO-CTCAE item scores at 12 months post-RT in the SBRT arm, as an indicator or persisting (consequential or "late") RT toxicity with SBRT to the head and neck region.

    Time frame: 6 years

  6. Patient Reported Outcomes utilizing FACT-HN

    proportion of patients between arms who have a meaningful worsening (12 points or greater) of QOL

    Time frame: 6 years

  7. Healthcare Resource Utilization utilizing EQ-5D-5L

    All enrolled participants who have received at least one fraction of protocol therapy are evaluable for health economics. Those who have completed the Health Utilities Index (EQ-5D-5L), will be evaluable for cost-utility analyses.

    Time frame: 6 years

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jan 2031, 68 months after the start.

Of 48 non-industry phase 3 interventional studies under Head and Neck Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 53 and three quarters within 108. This study's planned 68 months is below that.

Counting every sponsor, half of 66 studies reached it within 61 months; a quarter within 34 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 15, 2024
StartActual
Apr 7, 2025
Primary completionEst.
Jan 1, 2031
CompletionEst.
Jun 1, 2031
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Juravinski Cancer Centre at Hamilton Health Sciences · Hamilton, Canada
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    1 site added
    Show site
    • Juravinski Cancer Centre at Hamilton Health Sciences · Hamilton, Canada

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06641791
Lead sponsor
Canadian Cancer Trials Group
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Apr 7, 2025
Primary completion
Jan 1, 2031 (estimated)
Completion
Jun 1, 2031 (estimated)
Last update
Oct 14, 2026

Study contacts

Wendy Parulekar
Contact
wparulekar@ctg.queensu.ca
613-533-6430
Ian Poon
study chair · Odette Cancer Centre, Sunnybrook Health Sciences, UHN, Toronto, ON Canada

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion